MacroGenics price target raised to $51 from $35 at Stifel Stifel increased its price target on MacroGenics as the firm thinks the company is uniquely positioned to benefit from investor enthusiasm for targeted combination therapy in the immuno-oncology space. The firm believes the company has best-in-class technology, while recent data has increased Stifel's confidence in the company's approach. It keeps a Buy rating on the shares.
MacroGenics has reached 'intriguing entry point,' says Roth Capital Noting that MacroGenics' stock has tumbled nearly 40% over the past three months, Roth Capital says that the decline has significantly discounted the differentiation of the company's cancer treatment, MGA271, and offers an intriguing entry point for long-term investors focused on MacroGenics' DART-platform. Roth keeps a $45 price target and Buy rating on the shares.